Cargando…

Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs?

Cancer is one of the leading causes of death worldwide, and with the continuous development of life sciences and pharmaceutical technology, more and more antitumor drugs are being used in clinics to benefit cancer patients. However, the incidence of chemotherapy-induced cardiotoxicity has been conti...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yichuan, Jiang, Yueyao, Li, Min, Yu, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10194942/
https://www.ncbi.nlm.nih.gov/pubmed/37214453
http://dx.doi.org/10.3389/fphar.2023.1143361
_version_ 1785044124007661568
author Jiang, Yichuan
Jiang, Yueyao
Li, Min
Yu, Qian
author_facet Jiang, Yichuan
Jiang, Yueyao
Li, Min
Yu, Qian
author_sort Jiang, Yichuan
collection PubMed
description Cancer is one of the leading causes of death worldwide, and with the continuous development of life sciences and pharmaceutical technology, more and more antitumor drugs are being used in clinics to benefit cancer patients. However, the incidence of chemotherapy-induced cardiotoxicity has been continuously increasing, threatening patients’ long-term survival. Cardio-oncology has become a research hot spot, and the combination of nanotechnology and biomedicine has brought about an unprecedented technological revolution. Nanomaterials have the potential to maximize the efficacy and reduce the side effects of chemotherapeutic drugs when used as their carriers, and several nano-formulations of frequently used chemotherapeutic drugs have already been approved for marketing. In this review, we summarize chemotherapeutic drugs that are highly associated with cardiotoxicity and evaluate the role of nano-delivery systems in reducing cardiotoxicity based on studies of their marketed or R&D nano-formulations. Some of the marketed chemotherapy drugs are combined with nano-delivery systems that can effectively deliver chemotherapy drugs to tumors and cannot easily penetrate the endothelial barrier of the heart, thus decreasing their distribution in the heart and reducing the cardiotoxicity to some extent. However, many chemotherapy nanomedicines that are marketed or in R&D have not received enough attention in determining their cardiotoxicity. In general, nanomedicine is an effective method to reduce the cardiotoxicity of traditional chemotherapy drugs. However, cardiovascular complications in cancer treatment are very complex diseases, requiring the application of multiple measures to achieve effective management and prevention.
format Online
Article
Text
id pubmed-10194942
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101949422023-05-19 Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs? Jiang, Yichuan Jiang, Yueyao Li, Min Yu, Qian Front Pharmacol Pharmacology Cancer is one of the leading causes of death worldwide, and with the continuous development of life sciences and pharmaceutical technology, more and more antitumor drugs are being used in clinics to benefit cancer patients. However, the incidence of chemotherapy-induced cardiotoxicity has been continuously increasing, threatening patients’ long-term survival. Cardio-oncology has become a research hot spot, and the combination of nanotechnology and biomedicine has brought about an unprecedented technological revolution. Nanomaterials have the potential to maximize the efficacy and reduce the side effects of chemotherapeutic drugs when used as their carriers, and several nano-formulations of frequently used chemotherapeutic drugs have already been approved for marketing. In this review, we summarize chemotherapeutic drugs that are highly associated with cardiotoxicity and evaluate the role of nano-delivery systems in reducing cardiotoxicity based on studies of their marketed or R&D nano-formulations. Some of the marketed chemotherapy drugs are combined with nano-delivery systems that can effectively deliver chemotherapy drugs to tumors and cannot easily penetrate the endothelial barrier of the heart, thus decreasing their distribution in the heart and reducing the cardiotoxicity to some extent. However, many chemotherapy nanomedicines that are marketed or in R&D have not received enough attention in determining their cardiotoxicity. In general, nanomedicine is an effective method to reduce the cardiotoxicity of traditional chemotherapy drugs. However, cardiovascular complications in cancer treatment are very complex diseases, requiring the application of multiple measures to achieve effective management and prevention. Frontiers Media S.A. 2023-05-04 /pmc/articles/PMC10194942/ /pubmed/37214453 http://dx.doi.org/10.3389/fphar.2023.1143361 Text en Copyright © 2023 Jiang, Jiang, Li and Yu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Jiang, Yichuan
Jiang, Yueyao
Li, Min
Yu, Qian
Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs?
title Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs?
title_full Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs?
title_fullStr Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs?
title_full_unstemmed Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs?
title_short Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs?
title_sort will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs?
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10194942/
https://www.ncbi.nlm.nih.gov/pubmed/37214453
http://dx.doi.org/10.3389/fphar.2023.1143361
work_keys_str_mv AT jiangyichuan willnanomedicinebecomeagoodsolutionforthecardiotoxicityofchemotherapydrugs
AT jiangyueyao willnanomedicinebecomeagoodsolutionforthecardiotoxicityofchemotherapydrugs
AT limin willnanomedicinebecomeagoodsolutionforthecardiotoxicityofchemotherapydrugs
AT yuqian willnanomedicinebecomeagoodsolutionforthecardiotoxicityofchemotherapydrugs